Holland Capital realizes successful exit of Humeca to i4hi

Borne / Amsterdam, 5 July 2022 – Investment company Holland Capital realizes a successful exit of Humeca to fellow investor i4hi.

Humeca is a leading supplier of innovative products in the field of advanced skin grafting techniques and is the world market leader in the treatment of severe burns. The company’s internally developed revolutionary MEEK technology is superior to other transplant methods. In addition, Humeca offers various adjacent innovative products in the field of burn surgery. The company has built up a broad base of distributors serving customers in more than 70 countries worldwide with Humeca’s products.

Investment company Holland Capital offers active support

Holland Capital has been involved with Humeca as a shareholder since 2014. She has actively supported management in the strategic and commercial development of the company, including the opening of the US sales office. Hubert Verbeek, managing partner Holland Capital, about the exit: “We are extremely proud of what we have achieved together with the Humeca team over the past 8 years. We wish the team, together with i4hi, a lot of success in their next stage of growth.”

Arnoud van Velzen, managing director Humeca, “Supporting surgical burn teams and distributors worldwide in the application of our techniques is our passion. With great pride we look back on the collaboration with Holland Capital. With the participation of i4hi, we are excited to enter the next stage of growth.”